GLAND

Gland Pharma Share Price Gland Pharma

₹1,845.25
24.75 (1.36%)
  • Advice
  • Hold
29 March, 2024 15:16 BSE: 543245 NSE: GLANDISIN: INE068V01023

Start SIP in Gland Pharma

Start SIP

Gland Pharma Performance

Day Range

  • Low 1,803
  • High 1,851
₹ 1,845

52 Week Range

  • Low 861
  • High 2,194
₹ 1,845
  • Open Price1,843
  • Previous Close1,821
  • Volume98202

Gland Pharma Share Price

  • Over 1 Month 2.41%
  • Over 3 Month -4.66%
  • Over 6 Month 11.78%
  • Over 1 Year 47.07%

Gland Pharma Key Statistics

P/E Ratio 46.1
PEG Ratio -1.4
Market Cap Cr 30,393
Price to Book Ratio 3.8
EPS 49.5
Dividend 0
Relative Strength Index 54.59
Money Flow Index 50.55
MACD Signal -33.72
Average True Range 64.22
Gland Pharma Financials
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 1,0981,011884785
Operating Expenses Qtr Cr 728664625616
Operating Profit Qtr Cr 369347259169
Depreciation Qtr Cr 40403938
Interest Qtr Cr 1122
Tax Qtr Cr 95906633
Net Profit Qtr Cr 27725818879
IndicatorMar 2023
Total Revenue Annual Cr 3,857
Operating Expenses Annual Cr 2,598
Operating Profit Annual in Cr 1,019
Depreciation Cr 147
Interest Annual Cr 7
Tax Annual Cr 273
Net Profit Annual Cr 776
IndicatorMar 2023
Cash from Operating Activity Annual Cr 368
Cash from Investing Activity Annual Cr 1,208
Cash from Financing Annual Activity Cr 15
Net Cash Flow Annual Cr 1,591
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 7,953
Fixed Assets Annual Cr 1,748
Total Non Current Assets Annual Cr 1,885
Total Current Assets Annual Cr 6,888
Total Assets Annual Cr 8,773
IndicatorMar 2023
Book Value Per Share Annual Rs 483
ROE Annual % 10
ROCE Annual % 14
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 35
IndicatorDec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 1,5451,3731,209785
Operating Expenses Qtr Cr 1,1891,049915617
Operating Profit Qtr Cr 356324294168
Depreciation Qtr Cr 105816538
Interest Qtr Cr 5652
Tax Qtr Cr 91966732
Net Profit Qtr Cr 19219419479
IndicatorMar 2023
Total Revenue Annual Cr 3,865
Operating Expenses Annual Cr 2,600
Operating Profit Annual in Cr 1,025
Depreciation Cr 147
Interest Annual Cr 7
Tax Annual Cr 274
Net Profit Annual Cr 781
IndicatorMar 2023
Cash from Operating Activity Annual Cr 364
Cash from Investing Activity Annual Cr 1,208
Cash from Financing Annual Activity Cr 15
Net Cash Flow Annual Cr 1,587
IndicatorMar 2023
Total ShareHolders Funds Annual Cr 7,959
Fixed Assets Annual Cr 1,748
Total Non Current Assets Annual Cr 1,877
Total Current Assets Annual Cr 6,901
Total Assets Annual Cr 8,778
IndicatorMar 2023
Book Value Per Share Annual Rs 483
ROE Annual % 10
ROCE Annual % 14
Total Debt to Total Equity Annual -
EBDIT Annual Margin % 35

Gland Pharma Technicals

EMA & SMA

Current Price
₹1,845.25
24.75 (1.36%)
pointer
  • Bullish Moving Average
  • ___
  • 15
  • Bearish Moving Average
  • ___
  • 1
  • 20 Day
  • ₹1,794.80
  • 50 Day
  • ₹1,829.42
  • 100 Day
  • ₹1,799.46
  • 200 Day
  • ₹1,729.71
  • 20 Day
  • ₹1,765.03
  • 50 Day
  • ₹1,874.07
  • 100 Day
  • ₹1,838.83
  • 200 Day
  • ₹1,632.06

Gland Pharma Resistance and Support

PIVOT
₹1,833.17
Resistance
First Resistance 1,863.08
Second Resistance 1,880.92
Third Resistance 1,910.83
RSI 54.59
MFI 50.55
MACD Single Line -33.72
MACD -17.36
Support
First Resistance 1,815.33
Second Resistance 1,785.42
Third Resistance 1,767.58

Gland Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 103,704 6,136,166 59.17
Week 96,674 4,544,633 47.01
1 Month 197,296 11,143,273 56.48
6 Month 325,174 16,964,351 52.17

Gland Pharma Result Highlights

Gland Pharma Synopsis

NSE-Medical-Generic Drugs

Gland Pharma is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 3616.53 Cr. and Equity Capital is Rs. 16.47 Cr. for the Year ended 31/03/2023. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.
Market Cap 30,393
Sales 3,778
Shares in Float 6.92
No of funds 139
Yield
Book Value 3.82
U/D Vol ratio 0.8
LTDebt / Equity
Alpha 0.13
Beta 0.52

Gland Pharma

Owner NameDec-23Sep-23Jun-23Mar-23
Promoters 57.86%57.86%57.86%57.86%
Mutual Funds 21.34%19.79%20.48%20.25%
Insurance Companies 1.8%1.79%1.8%2.02%
Foreign Portfolio Investors 4.05%4.91%2.8%4.33%
Financial Institutions/ Banks 0.01%
Individual Investors 3.79%4.52%5.61%4.27%
Others 11.16%11.12%11.45%11.27%

Gland Pharma Management

Name Designation
Mr. Yiu Kwan Stanley Lau Chairman & Ind.Director
Mr. Srinivas Sadu Managing Director & CEO
Mr. Qiyu Chen Non Executive Director
Mr. Yao Fang Non Executive Director
Dr. Jia Ai (Allen) Zhang Non Executive Director
Mr. Udo Johannes Vetter Independent Director
Mr. Satyanarayana Murthy Chavali Independent Director
Mr. Essaji Goolam Vahanvati Independent Director

Gland Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Gland Pharma Corporate Action

Date Purpose Remarks
2024-02-14 Quarterly Results
2023-11-06 Quarterly Results
2023-08-07 Quarterly Results
2023-05-18 Audited Results & A.G.M.
2023-01-23 Quarterly Results

About Gland Pharma

Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well. 

In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world. 
 

Products offered by Gland Pharma Ltd.

  • Anti Malarials
  • Anti-Infectives
  • Anti-Neoplastics
  • Blood Related
  • Cardiac
  • Gastro Intestinal
  • Gynaecological
  • Hormones
  • Neuro / Cns
  • Ophthal / Otologicals
  • Others
  • Pain / Analgesics
  • Respiratory
  • Vitamins / Minerals / Nutrients

 

Gland Pharma Ltd is listed on 2 exchanges, and these are:

  • National Stock Exchange of India Ltd.
  • The Stock Exchange, Mumbai


Included in Indices

  • NIFTY 50 - No 
  • NIFTY next 50 - YES
  • NIFTY 100 - YES
  • S&P BSE 200 - YES
  • S&P BSE 250 large midcap index- YES
  • S&P BSE finance- NO

Other listing information

  • Incorporation date - March 20 1978
  • BSE group - A 
  • BSE Code - 543245
  • NSE - GLANDEQ

1978
PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.

1994
From a private limited company, it becomes a public limited company.

1996
Becomes the first company to establish a PFS facility in India.

2000
Signs its first Contract Manufacturing agreement for regulated markets

2007
Enters the US market with Ketorolac PFS

2013
Entered European markets with Tirofiban
The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.

2016
In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.

2017
Fosun Pharma acquired a majority stake in the company.

2018
Enoxaparin injection received US market approval in 2018.
The first ophthalmic product has been approved for sale in the United States.

Gland Pharma FAQs

What is Share Price of Gland Pharma ?

Gland Pharma share price is ₹1,845 As on 29 March, 2024 | 15:02

What is the Market Cap of Gland Pharma ?

The Market Cap of Gland Pharma is ₹30393.2 Cr As on 29 March, 2024 | 15:02

What is the P/E ratio of Gland Pharma ?

The P/E ratio of Gland Pharma is 46.1 As on 29 March, 2024 | 15:02

What is the PB ratio of Gland Pharma ?

The PB ratio of Gland Pharma is 3.8 As on 29 March, 2024 | 15:02

Is it a good time to invest in Gland Pharma Limited?

Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

What is the stock price CAGR of Gland Pharma Limited?

The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

Is Gland Pharma Limited debt-free?

Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

What is the ROE of Gland Pharma Limited?

The ROE of Gland Pharma Limited is 16% is which good.

Who is the Managing Director of Gland Pharma Limited?

Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

How to buy shares of Gland Pharma Ltd online?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

What are some of the competitors of Gland Pharma Ltd?

Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd. 

  • Cipla 
  • Sun Pharma 
  • Pfizer 
  • Lupin
  • Eris Life 
  • Aarti Drugs 
  • Hester Bio
  • RPG Life 
  • Bafna Pharma 
  • Jb Chemicals 

Q2FY23